Monopar Therapeutics assumed with an Overweight at Piper Sandler

Piper Sandler assumed coverage of Monopar Therapeutics (MNPR) with an Overweight rating and $76 price target The firm cites the potential of ALXN1840, a treatment for Wilson disease, for the Overweight rating. Monopar plans to file approval for ALXN1840 by early 2026 and Piper sees “strong odds of FDA approval, citing the Phase 3 data and the unmet need in Wilson disease specifically in patients with neurologic symptoms. It believes ALXN1840 has “significant value creating potential” for shareholders.